# NCT04459715 (NCT04459715)

> A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04459715
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: EMD Serono Research & Development Institute, Inc.
- Conditions: Squamous Cell Carcinoma of the Head and Neck
- Interventions: Xevinapant (Debio 1143); Cisplatin; Intensity Modulation Radiation Therapy (IMRT); Placebo
- Enrollment: 730
- Primary outcome: Event-Free Survival (EFS) as Assessed by Blinded Independent Review Committee (BIRC)

## Commentary we found

- X threads: 6
- Podcasts: 5
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04459715

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04459715", "email": "<work email>"}; the inbox owner confirms by the emailed link.